DBV Technologies S.A. (DBVT)

Market Cap	53.27M
Revenue (ttm)	12.52M
Net Income (ttm)	-102.09M
Shares Out	96.50M
EPS (ttm)	-1.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,277
Open	0.508
Previous Close	0.500
Day's Range	0.470 - 0.521
52-Week Range	0.470 - 2.140
Beta	0.86
Analysts	Strong Buy
Price Target	6.00 (+1,081.1%)
Earnings Date	Nov 6, 2024

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respirato...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 105
• Stock Exchange: NASDAQ
• Ticker Symbol: DBVT
• Website: https://www.dbv-technologies.com

Financial Performance

In 2023, DBV Technologies's revenue was $15.73 million, an increase of 224.69% compared to the previous year's $4.84 million. Losses were -$72.73 million, -24.46% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for DBVT stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 1,081.10% from the latest price.

Price Target

$6.0

(1,081.10% upside)

Analyst Consensus: Strong Buy